1. Home
  2. BGSF vs NSRX Comparison

BGSF vs NSRX Comparison

Compare BGSF & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BGSF Inc.

BGSF

BGSF Inc.

HOLD

Current Price

$5.90

Market Cap

53.2M

ML Signal

HOLD

NSRX

Nasus Pharma Ltd. Ordinary Shares

N/A

Current Price

$5.44

Market Cap

52.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BGSF
NSRX
Founded
2007
2019
Country
United States
Israel
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.2M
52.5M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
BGSF
NSRX
Price
$5.90
$5.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$9.00
$20.50
AVG Volume (30 Days)
37.2K
4.9K
Earning Date
03-11-2026
03-20-2026
Dividend Yield
35.34%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$263,687,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.14
N/A
P/E Ratio
N/A
N/A
Revenue Growth
71.60
N/A
52 Week Low
$2.91
$5.42
52 Week High
$8.22
$9.99

Technical Indicators

Market Signals
Indicator
BGSF
NSRX
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
BGSF
NSRX

About BGSF BGSF Inc.

BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: